One-Alpha contains alfacalcidol, a synthetic analogue of vitamin D₃ that is converted in the body to the active hormone calcitriol. It is classified within the broader “osteoporosis and bone health” therapeutic area and is supplied as a 0.25 µg capsule. In Hong Kong, One-Alpha is a prescription-only medication overseen by the Department of Health’s Pharmacy and Poisons Board.
Alfacalcidol (1-α-hydroxyvitamin D₃) bypasses the renal 1-α-hydroxylation step required for native vitamin D₃ to become active. After oral absorption, it is rapidly converted by hepatic enzymes to calcitriol, the hormonally active form of vitamin D. Calcitriol binds to vitamin D receptors in the intestines, kidneys, and bone, leading to:
The onset of action typically occurs within a few days, with peak biochemical effects on calcium metabolism observed after about one week of consistent dosing. The biological half-life reflects that of calcitriol, roughly 15 hours, meaning daily dosing maintains steady levels.
One-Alpha is approved in Hong Kong for the following indications:
These approvals align with the product’s ability to raise serum calcium and phosphate while normalising PTH levels, thereby supporting bone strength.
Clinical studies have explored alfacalcidol in several contexts beyond its approved labels:
Off-label use requires medical supervision and individualized risk assessment.
These events are often dose-related and reversible upon dose reduction or discontinuation.
Patients experiencing persistent vomiting, confusion, or a sudden rise in blood calcium should seek immediate medical attention.
Because interaction data for One-Alpha are limited, patients should disclose all prescription, over-the-counter, and herbal products to their prescriber.
This article provides educational information about One-Alpha and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Alfacalcidol is a pre-activated vitamin D analogue that does not require renal 1-α-hydroxylation, making it effective in patients with impaired kidney function, whereas standard vitamin D₃ must be converted by the kidneys to become active.
Yes, taking One-Alpha alongside calcium carbonate is common to ensure adequate calcium intake; however, total calcium intake should be monitored to avoid hypercalcaemia.
Bone mineral density changes are gradual; clinically meaningful improvements are typically observed after 12 months of consistent therapy combined with appropriate calcium and lifestyle measures.
Absorption is not highly time-dependent, but taking the capsule with a main meal that contains dietary fat can enhance gastrointestinal uptake.
The primary laboratory impact is on calcium, phosphate, and PTH levels. It does not interfere with standard liver or lipid panels but should be considered when interpreting calcium-related results.
Severe hypercalcaemia can cause visual disturbances such as blurred vision due to dehydration and electrolyte imbalance, prompting urgent medical evaluation.
Yes, alfacalcidol is frequently prescribed to dialysis patients to control secondary hyperparathyroidism, but dosing is individualized based on serum calcium, phosphate, and PTH.
Persistent nausea may indicate rising calcium levels; contacting a healthcare provider for possible dose adjustment or additional monitoring is advisable.
One-Alpha is a prescription medication; carry it in its original labelled container with a copy of the prescription, and be prepared to present it to customs or airline security if requested.
